Minerva Neurosciences Inc (NERV)
2.33
-0.03
(-1.27%)
USD |
NASDAQ |
May 01, 16:00
2.33
0.00 (0.00%)
After-Hours: 20:00
Minerva Neurosciences Enterprise Value: -24.41M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | -24.41M |
| April 29, 2024 | -24.06M |
| April 26, 2024 | -23.87M |
| April 25, 2024 | -23.92M |
| April 24, 2024 | -23.29M |
| April 23, 2024 | -23.22M |
| April 22, 2024 | -23.08M |
| April 19, 2024 | -23.57M |
| April 18, 2024 | -23.43M |
| April 17, 2024 | -23.64M |
| April 16, 2024 | -23.43M |
| April 15, 2024 | -23.99M |
| April 12, 2024 | -23.43M |
| April 11, 2024 | -23.15M |
| April 10, 2024 | -23.64M |
| April 09, 2024 | -23.15M |
| April 08, 2024 | -23.15M |
| April 05, 2024 | -23.15M |
| April 04, 2024 | -23.22M |
| April 03, 2024 | -23.15M |
| April 02, 2024 | -23.32M |
| April 01, 2024 | -23.22M |
| March 28, 2024 | -22.87M |
| March 27, 2024 | -23.43M |
| March 26, 2024 | -22.94M |
| Date | Value |
|---|---|
| March 25, 2024 | -22.31M |
| March 22, 2024 | -22.24M |
| March 21, 2024 | -22.80M |
| March 20, 2024 | -22.03M |
| March 19, 2024 | -22.38M |
| March 18, 2024 | -22.03M |
| March 15, 2024 | -21.40M |
| March 14, 2024 | -21.68M |
| March 13, 2024 | -21.19M |
| March 12, 2024 | -21.54M |
| March 11, 2024 | -21.26M |
| March 08, 2024 | -21.33M |
| March 07, 2024 | -23.01M |
| March 06, 2024 | -22.73M |
| March 05, 2024 | -22.73M |
| March 04, 2024 | -22.87M |
| March 01, 2024 | -22.52M |
| February 29, 2024 | -22.24M |
| February 28, 2024 | -21.12M |
| February 27, 2024 | -21.33M |
| February 26, 2024 | 6.642M |
| February 23, 2024 | 7.132M |
| February 22, 2024 | 9.790M |
| February 21, 2024 | 20.63M |
| February 20, 2024 | 20.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-40.53M
Minimum
Jun 22 2022
539.01M
Maximum
May 26 2020
58.23M
Average
11.33M
Median
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 7.811B |
| Janux Therapeutics Inc | 2.605B |
| ACADIA Pharmaceuticals Inc | 2.313B |
| Karyopharm Therapeutics Inc | 98.00M |
| Calidi Biotherapeutics Inc | 7.848M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.022M |
| Total Expenses (Quarterly) | 7.172M |
| EPS Diluted (Quarterly) | -1.20 |
| Earnings Yield | -200.0% |